FRM
ARQT icon

Fox Run Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Fox Run Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,736
Closed -$1.07M – 900
2025
Q4 		$1.07M Buy
36,736
+7,887
+27% +$202K 0.16% 187
2025
Q3 		$544K Buy
28,849
+17,582
+156% +$277K 0.08% 461
2025
Q2 		$158K Sell
11,267
-18,700
-62% -$262K 0.03% 774
2025
Q1 		$469K Buy
29,967
+13,021
+77% +$183K 0.07% 523
2024
Q4 		$236K Sell
16,946
-2,384
-12% -$26.1K 0.04% 715
2024
Q3 		$180K Sell
19,330
-9,509
-33% -$93.8K 0.04% 683
2024
Q2 		$268K Buy
+28,839
New +$261K 0.05% 580
2023
Q4 		– Sell
-11,216
Closed -$59.6K – 719
2023
Q3 		$59.6K Buy
+11,216
New +$95.4K 0.02% 656

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return